Crucible of COVID, ahoy 2021 & cancer deal trends: a BioCentury podcast
The New Year kicks off with the new — a new U.S. president readying to enter the White House with a new take on drug pricing, and investors eyeing new modalities — and too much of the same old — COVID, COVID, COVID. On the latest episode of the BioCentury This Week podcast, BioCentury editors discuss what industry buysiders are looking for in 2021, and what trends in cancer dealmaking mean for pharmas and small companies. They also discuss the key takeaways from conversations with a trio of R&D leaders — Paul Stoffels, Andrew Plump and Brett Haumann — who are among the leaders in the battle to create countermeasures against COVID-19.
Associate Editor Stephen Hansen, who is putting the final touches on BioCentury’s 2021 Financial Preview, said specialists expect industry to continue its torrid pace in financings, seeing few red flags ahead as they home in on companies developing therapies with new modalities.
Washington Editor Steve Usdin cautioned against expecting the incoming Biden administration to hold off on implementing new drug pricing policies because the pandemic is ongoing. “There’s a great deal of interest in Medicare drug prices,” he said. “And there are a lot of things that they can do using the powers of CMS — what’s called the CMMI [Center for Medicare and Medicaid Innovation] at CMS — to impose drug price controls.”
Hansen, who covers Europe and the U.K., said the Brexit deal gives biopharmas operating in the U.S. and on the Continent more regulatory certainty for the first time in four years, a topic he delved into in a report late last month.